Fibromyalgia is a chronic condition that affects 6% of the world’s population. It is characterized by persistent and frequently incapaciting widespread pain. The molecular basis of this disease remains incompletely understood, hindering both diagnosis and treatment.
In order to assist healthcare professionals in both of these areas, Fibrokit has been developed. This molecular test is based on the analysis of diagnostic biomarkers found un blood and stool samples, provinding a more accurate way of diagnosing and managing the diasease.
Fibromyalgia is associated with mitochondrial dysfunction. This organelle is responsible for producing the energy necessary in the cells to carry out the vital functions of the organism.
This dysfunction could be the main cause of chronic fatigue in patients. Hence, Fibrokit evaluates proteins associated with energy metabolism and mitochondrial oxidation in blood samples, being a valuable tool to identify such alterations in the diagnostic procedure.
Fibromyalgia is linked to intestinal imbalances that disrupt the communication between the gut, microorganisms and our body. This imbalance can negatively impact the immune, neurological and musculoskeletal systems.In previous studies conducted by Pronacera and other authors, it has been observed that fibromyalgia patients often experience problems such as altered intestinal permeability and microbiota, wich can worsen symptons such as chronic pain, fatigue, inmune defenses and even affect cognitive function.
Pronacera has identified a group of bacteria associated with this condition, which are evaluated using Fibrokit for precise clinical diagnosis.
To differentially diagnosis of fibromyalgia
alth weaknesses of each patient in order to get a personalized treatment
To predict the effectiveness of the current treatments that have been applied for people with fibromyalgia
To evaluate some of the potential causes of generalized pain, fatigue or gastrointestinal distrurbances
To established the most interesting parameters for the follow-up of people with fibromyalgia during the evolution and treatment of the pathology
To conduct Fibrokit, two samples are necessary:
Results are delivered 20 days after arrival at the laboratory, together with a detailed report.
Fibrokit is recommended for individuals experiencing:
